CFTR and cystic fibrosis: While its mechanism of action has not yet been directly correlated with the inhibition of LPO, it is noteworthy that this compound, by modulating the expression of mucins, particularly MUC5AC and MUC5B, which are crucial in CF pathology, in a manner similar to clinically used CFTR modulators, exhibited beneficial effects on lipid homeostasis and redox balance [124].